Neuromuscular Monitoring in Children (6 Months - 2 Years) With Electromyography and Acceleromyography
NCT ID: NCT06409260
Last Updated: 2025-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
120 participants
INTERVENTIONAL
2024-07-01
2025-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does Electromyography Improve Precision and Reliability of Neuromuscular Monitoring in Paediatric Patients
NCT06062290
Paired Assessment of Two Electromyographic Neuromuscular Monitors: Stimpod NMX450X Versus Datex-Ohmeda E-NMT
NCT04931901
Comparison of Onset of Neuromuscular Blockade With Electromyographic and Acceleromyographic Monitoring
NCT05120999
Train of Four Motor Point Stimulation and Monitoring
NCT02591108
Electromyographic and Acceleromyographic Monitoring in Restricted Arm Movement Surgical Setting
NCT04352140
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
NMBAs improve intubating conditions and prevent airway injury in children and infants (\<12 months of age). However, both patient age and type of anaesthesia influence onset and duration of action. Infants have shorter onset time of NMBAs compared to older children, and a higher proportion of infants had excellent intubating conditions compared to older children at two minutes after a dose of 0.15 mg/kg cisatracurium. Inhalation anaesthetics prolong recovery from cisatracurium compared to total intravenous anaesthesia and a longer duration of action is seen in infants compared to older children. However, as compared to adults, less profound neuromuscular blockade may be sufficient in children to establish satisfactory intubating conditions.
In children \< 3 years old, a study reported residual neuromuscular blockade (TOF (Train Of Four) ratio \< 0.9) among 8% of the included patients after administration of a single bolus of 0.1 mg/kg cisatracurium, but the actual proportion may have been as high as 20%. To prevent residual neuromuscular block, objective neuromuscular monitoring is recommended. In adults residual neuromuscular block may result in respiratory events (hypoxaemia and airway obstruction), unpleasant symptoms of muscle weakness, prolonged post-anaesthesia care unit stay, and an increased risk of postoperative pulmonary complications.
It is possible to monitor onset time and duration of action of NMBAs with electromyography (EMG) or acceleromyography (AMG) by train-of-four (TOF) stimulation of a peripheral nerve. Typically, the ulnar nerve is stimulated. In smaller children the tibial nerve can be used as an alternative. However, a recent study in adults reports that there may be important differences when comparing EMG and AMG TOF monitoring at the ulnar nerve with EMG detecting recovery of neuromuscular function later than AMG. Only one study in infants has reported that monitoring of neuromuscular function with AMG applied on the first toe may be a suitable alternative when the thumb is inaccessible. One recent study has reported the feasibility of monitoring the depth of neuromuscular block in infants using electromyography. No study has to our knowledge compared AMG to EMG in infants and small children.
The investigators hypothesize that AMG will indicate faster recovery (time to return to TOF 90%) from neuromuscular block than EMG A secondary aim of this study is to investigate agreement between the two monitors using a Bland Altman analysis comparing onset time and recovery from deep to moderate rocuronium-induced neuromuscular block with EMG and AMG.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
N. tibialis
Objective neuromuscular monitoring done on n. tibialis bilaterally
Acceleromyography (AMG)
Philips IntelliVue NMT Module
Electromyography (EMG)
Senzime TetraGraph
N. ulnaris
Objective neuromuscular monitoring done on n. ulnaris bilaterally
Acceleromyography (AMG)
Philips IntelliVue NMT Module
Electromyography (EMG)
Senzime TetraGraph
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acceleromyography (AMG)
Philips IntelliVue NMT Module
Electromyography (EMG)
Senzime TetraGraph
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Scheduled for elective surgery under general anaesthesia with intubation and use of rocuronium
* American Society of Anesthesiologists (ASA) physical status classification I to III
Exclusion Criteria
* Neuromuscular disease that may interfere with neuromuscular data
* Indication for rapid sequence induction
* Prone position
6 Months
2 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Matias Vested
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matias Vested
Principal Investigator, Medical Doctor, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matias Vested
Role: STUDY_CHAIR
Rigshospitalet University of Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMG vs AMG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.